Literature DB >> 8418044

Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection.

G Teti1, G Mancuso, F Tomasello.   

Abstract

Cytokines are suspected of playing an important role in the pathophysiology of septic shock. This study was undertaken to determine whether tumor necrosis factor alpha (TNF-alpha) induces the production of other cytokines and mediates mortality in a neonatal rat model of sepsis caused by group B streptococci (GBS). We have measured TNF-alpha, interleukin-1 alpha (IL-1 alpha), interleukin-6 (IL-6), and gamma interferon (IFN-gamma) levels in neonatal rats infected with different strains (H738, 259, and 90) and doses (1 50% lethal dose [LD50] and 5 90% lethal doses [LD90]) of type III GBS. TNF-alpha and IL-6 were detected by the L929 cytotoxicity and the B9 proliferation assays, respectively, in serial plasma samples. IL-1 alpha and IFN-gamma were measured in spleen homogenates by enzyme-linked immunosorbent assay kits by using antibodies raised against the corresponding mouse cytokines. Plasma TNF-alpha levels significantly rose above baseline values within 12 h after intraperitoneal challenge with 5 LD90 of GBS strain H738, corresponding to 3 x 10(3) CFU. A mean peak TNF-alpha concentration of 232 +/- 124 U/ml was reached at 20 h. Peak IL-1 alpha and IL-6 levels of 766 +/- 404 U/g and 1,033 +/- 520 U/ml, respectively, were reached at 24 h after bacterial challenge. Maximal spleen concentrations of IFN-gamma (449 +/- 283 U/g) were measured at 36 h. Concentrations of TNF-alpha, but not other cytokines, remained significantly elevated at 72 h, a time when mortality approached 100%. Significant correlations were found between concentrations of each of the cytokines tested and the logs of CFU concentrations in the blood. In order to ascertain whether TNF-alpha influenced the production of other cytokines, rat pups received two injections of anti-murine TNF-alpha or normal rabbit serum at 2 h before and at 26 h after challenge with live GBS. Plasma TNF-alpha bioactivity was undetectable in anti-TNF-alpha-treated animals, while IL-6 and IFN-gamma, but not IL-1 alpha, levels were significantly reduced, compared with normal serum controls. Rat pups pretreated with anti-TNF-alpha serum and infected with 1 and 5 LD90 of strains H738 and 259 showed enhanced early (48 to 72 h) survival. However, by 96 h this protection was no longer apparent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418044      PMCID: PMC302709          DOI: 10.1128/iai.61.1.227-235.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Proteolysis of the native murine IL 1 beta precursor is required to generate IL 1 beta bioactivity.

Authors:  C Günther; M Röllinghoff; H U Beuscher
Journal:  Immunobiology       Date:  1989-02       Impact factor: 3.144

2.  Tumor necrosis factor/cachectin and interleukin-1 secretion by cord blood monocytes from premature and term neonates.

Authors:  K B Weatherstone; E A Rich
Journal:  Pediatr Res       Date:  1989-04       Impact factor: 3.756

3.  Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.

Authors:  Y Fong; L L Moldawer; M Marano; H Wei; S B Tatter; R H Clarick; U Santhanam; D Sherris; L T May; P B Sehgal
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

4.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

5.  Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection.

Authors:  D C Helfgott; S B Tatter; U Santhanam; R H Clarick; N Bhardwaj; L T May; P B Sehgal
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

6.  Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice.

Authors:  G J Bancroft; K C Sheehan; R D Schreiber; E R Unanue
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

7.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response.

Authors:  S Nelson; G J Bagby; B G Bainton; L A Wilson; J J Thompson; W R Summer
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

9.  Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock.

Authors:  C Natanson; R L Danner; R J Elin; J M Hosseini; K W Peart; S M Banks; T J MacVittie; R I Walker; J E Parrillo
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

10.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  39 in total

1.  Interleukin-10 protects neonatal mice from lethal group B streptococcal infection.

Authors:  V Cusumano; F Genovese; G Mancuso; M Carbone; M T Fera; G Teti
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products.

Authors:  M Cuzzola; G Mancuso; C Beninati; C Biondo; C von Hunolstein; G Orefici; T Espevik; T H Flo; G Teti
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Soluble antigens from group B streptococci induce cytokine production in human blood cultures.

Authors:  C von Hunolstein; A Totolian; G Alfarone; G Mancuso; V Cusumano; G Teti; G Orefici
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.

Authors:  L Tissi; M Puliti; R Barluzzi; G Orefici; C von Hunolstein; F Bistoni
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates.

Authors:  Vitaliano Cusumano; Angelina Midiri; Valentina Valeria Cusumano; Antonella Bellantoni; Giuseppe De Sossi; Giuseppe Teti; Concetta Beninati; Giuseppe Mancuso
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Group B streptococcus-induced nitric oxide production in murine macrophages is CR3 (CD11b/CD18) dependent.

Authors:  K J Goodrum; L L McCormick; B Schneider
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Tumor necrosis factor alpha acts as an autocrine second signal with gamma interferon to induce nitric oxide in group B streptococcus-treated macrophages.

Authors:  K J Goodrum; J Dierksheide; B J Yoder
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Effects of fibronectin and group B streptococci on tumour necrosis factor-alpha production by human culture-derived macrophages.

Authors:  E B Peat; N H Augustine; W K Drummond; J F Bohnsack; H R Hill
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

9.  Progressive Control of Streptococcus agalactiae-Induced Innate Inflammatory Response Is Associated with Time Course Expression of MicroRNA-223 by Neutrophils.

Authors:  Maud Deny; Marta Romano; Olivier Denis; Georges Casimir; Mustapha Chamekh
Journal:  Infect Immun       Date:  2020-11-16       Impact factor: 3.441

10.  Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci.

Authors:  Hiroshige Mikamo; Atul K Johri; Lawrence C Paoletti; Lawrence C Madoff; Andrew B Onderdonk
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.